As part of the merger, the combined company will be named Horizon Pharma PLC and will be organized under the laws of Ireland. in a cash-and-stock deal valued at about $660 million, as the specialty pharmaceutical company sought to expand its range of products. Horizon Pharma Inc (NDAQ:HZNP) agreed to acquire Vidara Therapeutics Inc. "Horizon Pharma to Acquire Vidara in $660 Million Deal". ^ "Horizon Pharma to Acquire Vidara Therapeutics International".^ "Teva wins controversial PhRMA bid despite protests from branded rivals – FiercePharma"."FTC sues to block Amgen acquisition of Horizon Therapeutics". "FTC sues to stop drugmaker Amgen from completing $27.8 billion deal". "Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war". "Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal". ^ a b Mishra, Manas Satija, Bhanvi (12 December 2022)."Biopharmaceutical company signs lease for research and development facility in Rockville". ^ "Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela buy".^ "FDA Approves TEPEZZA (TM) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)".^ "SEC Form 8-K: Horizon Therapeutics plc".^ "BRIEF-Horizon Pharma Plc to acquire River Vision Development Corp".^ "Horizon Pharma Buys Crealta Holdings for $510M".^ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B".^ "Horizon Pharma Picks Up Nuvo's Osteoarthritis Pain Drug Pennsaid 2% – GEN News Highlights – GEN".^ Vanessa Houlder Vincent Boland James Politi (29 April 2014).Bloomberg Special Reports: Corporate Tax Inversions ^ a b "Amgen completes $27.8 billion Horizon deal".^ a b "SEC Form 10-K: Horion Pharma public limited company".^ "Amgen to buy Horizon Therapeutics in $26.4 billion deal".^ "US Biopharma Firm Amgen To Acquire Horizon Therapeutics For $28 Bn".Horizon Therapeutics sales by region (2017) Region The acquisition was completed in October 2023 after mutually resolving the litigation. In May 2023, the Federal Trade Commission said it would sue to block the deal in an attempt to control drug prices. The company was reportedly the center of a bidding war between Amgen, Johnson & Johnson and Sanofi. In December 2022, the company announced it would be acquired by Amgen for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium). In February 2021, the business announced it would acquire Viela Bio Inc for around $3 billion ($53 per share). Horizon believed it could reach $1 billion peak sales in the US alone. In January 2020 – after showing very strong PhIII data – it was approved for the treatment of thyroid eye disease (TED), a rare vision-threatening disease that previously had no FDA-approved treatment options. On May 2, 2019, shareholders of the company approved the change of the company's name from Horizon Pharma plc to Horizon Therapeutics plc. In 2017, Horizon announced its intention to acquire River Vision Development Corp for $145 million and to continue the development of teprotumumab. In September 2016, the company announced the acquisition of Raptor Pharmaceutical for $800 million, adding Procysbi and Quinsair to its rare drug portfolio. In December, the company acquired Crealta Holdings for $510 million. In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizon's orphan disease drug portfolio. In October 2014, the company acquired the US sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million. In 2014, Horizon executed a tax inversion to move its legal headquarters to Ireland to avail itself of Ireland's low tax rates and beneficial corporate tax system.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |